📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
56 announcements match the current filters (relevance ≥ 5).
IKS Health to Acquire TruBridge for $26.25 Per Share to Expand US Healthcare Footprint
Inventurus Knowledge Solutions Limited (IKS) has signed a definitive agreement to acquire US-based TruBridge for $26.25 per share in cash. The acquisition, expected to close in Q3 2026, will be financed primarily through new debt underwritten by Citibank, JPMorganChase, and Deutsche Bank. This strategic move aims to combine IKS's AI-driven care enablement with TruBridge's EHR and revenue cycle management solutions, specifically targeting the rural and community hospital market in the US. The combined entity will serve over 2,000 healthcare organizations and more than 150,000 clinicians.
Key Highlights
Acquisition price of $26.25 per share in cash for TruBridge common stock
Combined entity to support 2,000+ healthcare organizations and 150,000+ clinicians
Financing secured via new term loans from Citibank, JPMorganChase, and Deutsche Bank
Major TruBridge shareholders representing 27% of stock have already agreed to the deal
Transaction expected to close in the third calendar quarter of 2026
👀 What to Watch
Investors should monitor the company's leverage and interest coverage ratios as the deal is primarily debt-funded. The acquisition significantly scales IKS's US presence, making it a key growth driver to watch over the next 18 months.
IKS to Acquire US-based TruBridge Inc. for USD 565 Million
Inventurus Knowledge Solutions (IKS) has announced the 100% acquisition of TruBridge Inc., a NASDAQ-listed US healthcare IT provider, for USD 565 million. The deal will be financed through a new debt facility of up to USD 670 million from global lenders including Citibank, Deutsche Bank, and JPMorgan. TruBridge reported a turnover of USD 346.8 million in CY 2025 and serves over 700 hospitals, providing a significant boost to IKS's US market presence. This acquisition allows IKS to diversify into the high-margin SaaS EHR and integrated care enablement segments.
Key Highlights
Acquisition of 100% stake in TruBridge Inc. for a total consideration of USD 565 million.
TruBridge reported a consolidated turnover of USD 346.8 million for CY 2025 with a presence in the US and India.
Financing secured via USD 670 million debt facilities to cover acquisition costs and refinancing.
Strategic expansion into the sticky SaaS Electronic Health Record (EHR) and Revenue Cycle Management (RCM) segments.
Transaction expected to be completed within 180 days from the announcement date of April 23, 2026.
👀 What to Watch
Investors should view this as a major growth milestone that significantly scales IKS's US operations, though the high debt levels for financing warrant close monitoring of future interest coverage ratios. Watch for integration synergies and the impact on consolidated margins in upcoming quarters.
IKS Health Launches MyCareHub AI Platform; Reports Up To 9.4% Rise In Patient Payments
Inventurus Knowledge Solutions (IKS Health) has launched MyCareHub, a first-of-its-kind agentic AI platform for patient engagement, at the 2026 AMGA conference. The platform is integrated with Epic, the leading US electronic health record system, significantly expanding its market potential. Real-world data from its implementation at OrthoNY shows a 9.4% increase in patient payments per visit and an 8.25% rise in net payments. This launch reinforces IKS's strategy to leverage AI for improving financial outcomes for large-scale healthcare providers in the US.
Key Highlights
Launched MyCareHub, an agentic AI platform integrated with Epic and available in the Epic Connection Hub.
Reported a 9.4% increase in patient payments per visit following implementation at OrthoNY.
Achieved an 8.25% increase in net payments per visit and a 4.7% rise in total patient collections.
The platform utilizes multi-agent behavioral algorithms and longitudinal patient memory to automate engagement.
Recognized by Google Cloud with the 2025 DORA Award for AI-driven human expertise augmentation.
👀 What to Watch
Investors should monitor the adoption rate of MyCareHub across IKS's client base, as its proven ROI and Epic integration could drive significant high-margin revenue growth. The successful deployment of agentic AI positions the company as a leader in the evolving US healthcare RCM market.
IKS Confirms Non-Binding Discussions for $600 Million Acquisition of TruBridge
Inventurus Knowledge Solutions (IKS) has confirmed that its wholly owned subsidiary is in discussions for a potential acquisition of TruBridge, Inc. for approximately $600 million. The company clarified that while discussions have taken place, no definitive or binding agreements have been signed as of April 14, 2026. The potential transaction remains subject to various contingencies, including board approvals and further negotiations. Investors should note that there is currently no assurance that the deal will be consummated or what the final terms might be.
Key Highlights
Company confirms subsidiary participation in discussions for a potential $600 million acquisition.
Clarification issued following a news report in The Economic Times regarding the Jhunjhunwala-backed firm.
Discussions are currently non-binding with no definitive agreements executed to date.
Transaction is subject to ongoing negotiations, board approvals, and other regulatory contingencies.
Company maintains that no undisclosed material information exists that would impact trading activity.
👀 What to Watch
Investors should treat this as a high-probability expansion intent but wait for formal execution of binding agreements before pricing in the acquisition. Monitor for further disclosures regarding funding structures and valuation multiples for the $600 million deal.
IKS Completes USD 20.99 Million Investment in US Subsidiary IKS Inc.
Inventurus Knowledge Solutions Limited (IKS) has successfully completed its planned investment in its wholly-owned US subsidiary, Inventurus Knowledge Solutions, Inc. The company acquired 32,635 shares in this second tranche for a total consideration of USD 20,990,505. This transaction concludes the investment process that was initially approved by the Board on March 13, 2026. The move strengthens the capital base of the subsidiary to support its international business operations.
Key Highlights
Acquisition of 32,635 shares of wholly-owned subsidiary IKS Inc.
Second tranche investment amount totals USD 20,990,505.
Completion of the investment cycle initiated and disclosed in March 2026.
Strengthens the financial position of the company's primary US-based entity.
👀 What to Watch
Investors should monitor the performance of the US subsidiary as this capital infusion is likely intended for scaling North American operations. The completion of this planned investment removes any uncertainty regarding the company's immediate capital allocation strategy.
IKS Health Announces Strategic Acquihire of AI-Native Company ThinkDTM
Inventurus Knowledge Solutions (IKS) has completed the strategic acquihire of ThinkDTM, an AI-native product and digital services firm, to bolster its technological capabilities. The move integrates a specialized team of AI and product design experts, with ThinkDTM founder Tij Bedi joining as EVP and GM of Patient Access and Innovation. This acquisition is designed to accelerate the development of agentic AI workflows for patient scheduling, registration, and insurance verification. By enhancing its AI-led revenue optimization portfolio, IKS aims to drive higher operational efficiency and market differentiation in the healthcare technology sector.
Key Highlights
Strategic acquihire of ThinkDTM, an AI-native product, strategy, and digital services company
Appointment of Tij Bedi as Executive Vice President and General Manager to lead Patient Access and Innovation
Integration of specialized AI technology experts to scale agentic AI workflows and revenue optimization
Focus on transforming patient access solutions including scheduling, registration, and insurance eligibility verification
Strengthens IKS Health's position as a leader in AI-driven Revenue Cycle Management (RCM) services
👀 What to Watch
Investors should monitor how this integration improves IKS's service delivery margins through AI automation. The addition of specialized AI talent is a positive indicator of the company's commitment to maintaining its competitive edge in the US healthcare market.
IKS Completes $19 Million Investment in US Subsidiary IKS Inc.
Inventurus Knowledge Solutions Limited (IKS) has executed the first tranche of its investment in its wholly owned subsidiary, Inventurus Knowledge Solutions, Inc. (IKS Inc.). The company acquired 29,541 shares for a total consideration of USD 19,000,476. This transaction follows the Board's approval granted on March 13, 2026, for further capital infusion. The investment is aimed at bolstering the subsidiary's operations and supporting the group's international growth strategy.
Key Highlights
Acquired 29,541 shares of wholly owned subsidiary IKS Inc. in the first tranche.
Total investment amount for this transaction stands at USD 19,000,476.
The move follows a strategic Board approval dated March 13, 2026.
Capital infusion is intended to strengthen the US-based entity's financial position for expansion.
👀 What to Watch
Investors should view this as a commitment to international growth; monitor the US subsidiary's contribution to consolidated revenue in future earnings reports.
IKS Health and Certilytics Expand AI Partnership to Automate 70% of Prior Auth Workflows
Inventurus Knowledge Solutions (IKS) has expanded its strategic collaboration with Certilytics to bridge the payer-provider gap using Agentic AI and human-in-the-loop oversight. The partnership integrates Certilytics’ BrainstormAI® with IKS’s platform to automate complex administrative tasks while maintaining clinical accuracy. A primary goal is the autonomous handling of over 70% of prior authorization workflows, significantly reducing administrative burdens for US healthcare providers. This move strengthens IKS's value proposition in the high-growth healthcare technology and care enablement sector.
Key Highlights
Expanded partnership with Certilytics to deploy Agentic AI for healthcare systems of action.
Targeting autonomous handling of more than 70% of all prior authorization workflows.
Integration of BrainstormAI® Studio and CertHLM™ with IKS Health’s Agentic Care Enablement Platform.
Focus on three strategic use cases: prior authorization transparency, member engagement, and consumer price transparency.
👀 What to Watch
Investors should view this as a positive technological advancement that could improve IKS's margins and deepen its integration with large US health systems. Monitor the adoption rate of these AI-driven services as they transition from pilot to full-scale deployment.
IKS Health Wins Three Top 2026 Black Book Awards for AI-Driven RCM and Clinical Services
IKS Health has secured top rankings in three major categories in the 2026 Black Book Research awards, marking its 13th consecutive year of leadership in clinical documentation. The company ranked first in 14 out of 18 KPIs for clinical documentation and 9 out of 18 for both AI-driven RCM and medical coding. This recognition comes at a time when 35% to 55% of healthcare providers surveyed plan to increase spending in these segments during 2026. These awards validate IKS Health's competitive moat and technological leadership in the high-growth US healthcare technology services market.
Key Highlights
Ranked #1 in Clinical Documentation & AI Services for the 13th consecutive year, leading in 14 out of 18 performance indicators.
Secured the top spot in AI-driven RCM for the 2nd year and Medical Coding for the 4th consecutive year.
Black Book survey indicates 35% to 55% of providers expect to increase spending in AI-driven RCM and coding in 2026.
Ranked #1 in 9 out of 18 KPIs for both AI-driven RCM and Medical Coding categories, including denial prevention and specialty depth.
👀 What to Watch
These accolades reinforce IKS Health's strong market position and technological edge in the US healthcare RCM space. Investors should monitor if this industry recognition translates into accelerated client acquisition and revenue growth in the upcoming fiscal periods.
Inventurus Knowledge Solutions to Invest USD 40 Million in US Subsidiary IKS Inc.
Inventurus Knowledge Solutions (IKS) has approved a further investment of up to USD 40 million in its wholly-owned US subsidiary, IKS Inc. The investment will be conducted in tranches, with the first USD 20 million tranche expected to be completed by May 31, 2026, at a price of USD 643.19 per share. IKS Inc. is a key revenue driver for the company, reporting a turnover of INR 6,941.11 million in FY 2024-25. This capital infusion is aimed at supporting the subsidiary's business activities in the US healthcare technology sector.
Key Highlights
Total investment of up to USD 40 million approved for US-based subsidiary IKS Inc.
First tranche of USD 20 million involves acquiring 31,096 shares at USD 643.19 each.
IKS Inc. reported FY 2024-25 revenue of INR 6,941.11 million, showing stable performance.
The investment is expected to be completed by May 31, 2026, through cash consideration.
IKS Inc. provides technology-enabled care enablement platforms for US healthcare providers.
👀 What to Watch
Investors should monitor the utilization of this capital for potential technology upgrades or market expansion in the US. The continued focus on the US healthcare market remains a core growth driver for the company.
IKS Reports 24% YoY Revenue Growth in Q3 FY26 with Minimal 1.5% Headcount Increase
Inventurus Knowledge Solutions (IKS) reported a strong Q3 FY26 with 24% YoY revenue growth in Rupee terms and 19% in Dollar terms. The company demonstrated significant operational leverage, achieving this growth with only a 1.5% increase in headcount (13,350 total), highlighting its successful transition to an AI-native platform. IKS is currently outperforming the outsourced healthcare market growth of 12%, indicating substantial market share gains. Management emphasized progress in autonomous clinical documentation and medical coding solutions to further decouple revenue from labor costs.
Key Highlights
Revenue grew 24% YoY in INR terms and 19% in USD terms for the quarter ended December 31, 2025.
Headcount increased by only 1.5% YoY to 13,350, demonstrating a break in linearity between revenue and people growth.
Company is growing at double the rate of the $35 billion outsourced healthcare market, which grows at 12% annually.
Successfully deployed AI-native agentic workflows for clinical documentation, medical coding, and prior authorization.
Targeting a total addressable market (TAM) of $260 billion in US healthcare administrative tasks.
👀 What to Watch
Investors should view the decoupling of headcount from revenue as a significant margin expansion catalyst. The company's ability to outpace market growth while maintaining a flat workforce suggests a strong competitive moat in AI-led healthcare services.
IKS Q3 FY26: Revenue Up 24% YoY to ₹8,150 Mn; PAT Surges 41% with Strong Margin Expansion
Inventurus Knowledge Solutions (IKS) reported a strong Q3 FY26 with revenue rising 24% YoY to ₹8,150 million and PAT increasing 41.4% to ₹1,833 million. The company achieved an impressive EBITDA margin of 34.6%, up from 30.5% in the same quarter last year. Cash flow generation remains robust, with Free Cash Flow (FCF) growing 79.9% YoY, while net debt was significantly reduced to ₹1,455 million. Key deal wins with VitalMD and StrideCare highlight continued momentum in the US healthcare enablement market.
Key Highlights
Revenue from operations reached ₹8,150 million, a 24% YoY increase (19% in USD terms).
EBITDA grew 40.4% YoY to ₹2,816 million, maintaining a high margin of 34.6%.
Adjusted PAT stood at ₹2,154 million, up 48% YoY, after accounting for non-recurring debt refinancing costs.
Net debt decreased sharply to ₹1,455 million from ₹4,159 million YoY, strengthening the balance sheet.
The company reported a high Return on Equity (ROE) of 31% and an EPS of ₹11 for the quarter.
👀 What to Watch
The company demonstrates strong fundamental growth and efficient capital management; investors should monitor the scalability of its AI-native platform and client retention as key growth drivers.
IKS Health Q3 FY26: Revenue up 24% to INR 8,150 Mn, PAT Surges 41% YoY
Inventurus Knowledge Solutions (IKS Health) reported a robust Q3 FY26 with revenue reaching INR 8,150 Mn, a 24% YoY increase. Net profit (PAT) grew significantly by 41% YoY to INR 1,833 Mn, supported by strong EBITDA margins of 35%. The company continues to benefit from US healthcare outsourcing trends and expanded partnerships with major entities like StrideCare and a top 5 health system. Management's focus on AI-driven care enablement platforms is driving both top-line growth and operational efficiency.
Key Highlights
Revenue increased 24% YoY to INR 8,150 Mn; PAT rose 41% YoY to INR 1,833 Mn.
EBITDA grew 40% YoY to INR 2,816 Mn with a healthy margin of 35% compared to 31% in Q3 FY25.
Expanded long-term partnership with VitalMD for AI-driven Scribble Suite solutions across 800+ providers.
New partnership with StrideCare for end-to-end revenue cycle management and clinical coding.
Expanded RCM and Value-Based Care partnership with a top 5 US health system into additional regions.
👀 What to Watch
The strong financial performance and margin expansion suggest high scalability and operating leverage; investors should maintain a positive outlook. Monitor the continued adoption of AI-driven 'Scribble Suite' as a key differentiator for long-term growth.
IKS Reports 24% YoY Revenue Growth to ₹8,149.5 Million in Q3 FY26
Inventurus Knowledge Solutions (IKS) reported a strong consolidated revenue of ₹8,149.5 million for the quarter ended December 31, 2025, representing a 24% increase compared to the same quarter last year. The company's nine-month revenue reached ₹23,361.36 million, up from ₹19,400.38 million in the previous year, showing consistent growth. While revenue grew, employee benefit expenses also rose to ₹4,059.09 million, reflecting the scale-up in operations. The standalone revenue showed even more significant growth, jumping nearly 67% YoY to ₹4,035.28 million.
Key Highlights
Consolidated revenue from operations grew 24% YoY to ₹8,149.50 million in Q3 FY26.
Nine-month consolidated revenue reached ₹23,361.36 million, compared to ₹19,400.38 million in the prior year period.
Standalone revenue for the quarter surged 67% YoY to ₹4,035.28 million from ₹2,413.13 million.
Total consolidated income for Q3 FY26 stood at ₹8,205.03 million versus ₹6,841.50 million in Q3 FY25.
Employee benefit expenses for the quarter were ₹4,059.09 million, up from ₹3,833.74 million in the previous year's quarter.
👀 What to Watch
Investors should focus on the company's ability to maintain margins as it scales, given the rising employee and finance costs. The strong top-line growth indicates healthy demand for its healthcare-focused knowledge solutions.
IKS: Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025
Inventurus Knowledge Solutions Limited (IKS) announced the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The results were approved at a Board Meeting held on October 30, 2025. The meeting commenced at 07:00 P.M. IST and concluded at 07:55 P.M. IST. The financial results have been reviewed by Price Waterhouse Chartered Accountants LLP.
Key Highlights
Unaudited consolidated financial results include total revenues of ₹533.97 million for one subsidiary for the quarter ended September 30, 2025.
Unaudited consolidated financial results include total net profit after tax of ₹30.69 million for one subsidiary for the quarter ended September 30, 2025.
Unaudited consolidated financial results include total revenues of ₹1,146.02 million for one subsidiary for the period from April 01, 2025 to September 30, 2025.
Unaudited consolidated financial results include total net profit after tax of ₹98.75 million for one subsidiary for the period from April 01, 2025 to September 30, 2025.
The Group's share of net loss after tax is ₹14.18 million for the quarter ended September 30, 2025, in respect of one associate.
👀 What to Watch
Investors should review the detailed financial results and limited review reports to understand the company's performance. Monitor the company's future announcements for further updates.
IKS grants 470,000 employee stock options under ESOP 2022
Inventurus Knowledge Solutions Limited (IKS) has announced the grant of 470,000 employee stock options under its Employee Stock Option Plan 2022. Each option is convertible into one fully paid-up equity share with a face value of Re. 1. The exercise price for these options is set at ₹1,667.50 per option, which is not less than the closing market price on December 3, 2025. The options can be exercised anytime during the period of continuous active employment from the date of vesting.
Key Highlights
Granted 470,000 employee stock options.
Exercise price is ₹1,667.50 per option.
Face value of each equity share is Re. 1.
Options granted under Employee Stock Option Plan 2022.
👀 What to Watch
Investors should monitor the dilution effect of these options as they are exercised. Keep an eye on the company's performance and how these options incentivize employees.
